- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on EGFR Mutated EGFR TKI Naive Metastatic NSCLC
Total 131 results
-
AstraZenecaCompletedLocally Advanced or Metastatic EGFR Mutated NSCLC.Taiwan
-
Sierra Oncology, Inc.TerminatedEGFR Mutated EGFR TKI Naive Metastatic NSCLCUnited States
-
Fujian Cancer HospitalNot yet recruitingNSCLC | EGFR | Third-generation TKI
-
Shenzhen People's HospitalUnknownNSCLC | Apatinib | EGFR-TKIChina
-
AstraZenecaCompletedLocally Advanced or Metastatic EGFR(+) NSCLC PatientsChina
-
Astellas Pharma IncTerminatedEGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating MutationsJapan
-
AstraZenecaCompletedLocally Advanced or Metastatic EGFR T790M+ NSCLCCanada, Korea, Republic of, Taiwan
-
Sun Yat-sen UniversityRecruitingNon-small Cell Lung Cancer (NSCLC) | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation | Somatic Mutation | Germline MutationsChina
-
Blueprint Medicines CorporationActive, not recruitingNeoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Metastatic Lung Cancer | Antineoplastic Agents | Brain Metastases | Lung Neoplasm Malignant | EGFR... and other conditionsUnited States, Canada, Korea, Republic of, Japan, Taiwan
-
Molecular Partners AGTerminatedEGFR-mutated NSCLC (Disorder)United States
-
AstraZenecaCompletedEGFR Mutation Status in aNSCLC PatientsKorea, Republic of, Russian Federation, Malaysia, China, Australia, Taiwan, Thailand, Indonesia, Singapore
-
The First Affiliated Hospital of Guangzhou Medical...Unknown
-
Shenzhen People's HospitalUnknown
-
AstraZenecaCompletedEGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.Italy, Spain, United Kingdom, Sweden, Japan, Netherlands, Germany, France
-
AstraZenecaNo longer available
-
GenoSaberSun Yat-sen University; Shanghai Chest Hospital; Shanghai Pulmonary Hospital,...UnknownNon Small Cell Lung Cancer | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation
-
ETOP IBCSG Partners FoundationAstraZenecaActive, not recruitingNSCLC Stage IV | EGFR Gene MutationSingapore, Sweden, Korea, Republic of, Spain, Switzerland, Netherlands, Italy, Poland
-
Tianjin Medical University Cancer Institute and...Not yet recruitingNSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
-
Sichuan Provincial People's HospitalUnknownStage IV EGFR Mutated NSCL With Brain MetastasesChina
-
Chinese University of Hong KongPamela Youde Nethersole Eastern HospitalCompleted
-
AstraZenecaCompletedCaucasian Patients With EGFR Mutation Positive Advanced NSCLCBulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
-
Astellas Pharma Global Development, Inc.WithdrawnSubjects With NSCLC With an EGFR Activating Mutation
-
Incyte CorporationTerminatedAdvanced or Metastatic Solid Tumors | FGFR Mutations | FGFR TranslocationsUnited States
-
Henan Cancer HospitalUnknownAdvanced NSCLC With EGFR MutationChina
-
PfizerRecruitingEGFR Mutation-positive Inoperable or Reccrent NSCLCJapan
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityNot yet recruitingChemotherapy | Surgery | Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR TKI
-
China Medical University HospitalNot yet recruitingNon-small Cell Lung Cancer | EGFR Gene Mutation | EGFR-TKI Resistant Mutation
-
Radiotherapy Oncology Centre "Santa Maria" HospitalPaola Anselmo,MD; Michelina Casale,PhD; Fabio Trippa,MDRecruitingNSCLC | Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Oligometastatic Disease | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Non-Small Cell Adenocarcinoma and other conditionsItaly
-
Tianjin Medical University Cancer Institute and...RecruitingNon-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle DeregulationChina
-
Second Xiangya Hospital of Central South UniversityThe First Affiliated Hospital of Nanchang University; Xiangya Hospital of Central... and other collaboratorsRecruitingLung Cancer, Non-small Cell | Circulating Tumor DNA | EGFR Gene Mutation | EGFR-TKI Resistant Mutation | Primary ResistanceChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | KRAS Gene Mutation | Metastatic Malignant Solid Neoplasm | EGFR Gene Mutation | ERBB2 Gene Amplification | ERBB2 Gene Mutation | EGFR Gene Amplification | ERBB3 Gene Mutation | ERBB4 Gene MutationUnited States
-
Second Affiliated Hospital of Nanchang UniversityJiangsu Hansoh Pharmaceutical Co., Ltd.Not yet recruitingNSCLC | EGFR Activating Mutation | Leptomeningeal MetastasisChina
-
Dr Joanne CHIURecruitingALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung CancerHong Kong
-
Peking Union Medical CollegeRecruitingNSCLC | Brain Metastases | Furmonertinib | EGFR-mutationChina
-
Black Diamond Therapeutics, Inc.RecruitingNon-Small Cell Lung Cancer | NSCLC | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | EGF-R Positive Non-Small Cell Lung Cancer | Advanced Lung Carcinoma | EGFR-TKI Resistant Mutation | Advanced Non-Small Cell Squamous Lung Cancer | Epidermal Growth Factor Receptor C797S | Epidermal...Korea, Republic of, United States
-
Daping Hospital and the Research Institute of Surgery...CompletedNSCLC | Advanced Cancer | EGFR Gene Amplification | Stage IV NSCLC | Stage IIIB NSCLCChina
-
The University of Hong KongUnknownNSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIBHong Kong
-
ArriVent BioPharma, Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768IUnited States, Australia, Spain, Italy, United Kingdom, France, China, Korea, Republic of, Canada, Japan, Netherlands
-
Shanghai Cancer Hospital, ChinaUnknownLung Cancer Stage IV,EGFR-mutant,TKI,PD-L1,SBRTChina
-
Peking Union Medical CollegeRecruitingNSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB | NSCLC, RecurrentChina
-
Fujian Cancer HospitalEnrolling by invitationEGFR/ ALK-negative Advanced NSCLCChina
-
University Hospital, EssenCompletedNSCLC | EGFR T790M | FDG-PETGermany
-
Fudan UniversityCompletedNSCLC Stage IV | EGFR Activating MutationChina
-
Yonsei UniversityUnknownCompletely Resected NSCLC With Common EGFR MutationsKorea, Republic of
-
Degan LuWu Jieping Medical FoundationNot yet recruitingLung Cancer | Anlotinib | TKI Resistance | EGFR Sensitive Mutation | Pianzumab
-
Baodong QinUnknownNSCLC Stage IV | Anlotinib | EGFR T790M-negative | JS001China
-
Rain Oncology IncTerminatedNSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB FusionUnited States, Canada, Hong Kong
-
West China HospitalRecruitingBRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal AntibodyChina
-
Centre Francois BaclesseHoffmann-La Roche; Groupe Francais De Pneumo-CancerologieTerminatedNSCLC Patients With EGFR Activating MutationFrance
-
TYK Medicines, IncRecruitingNSCLC | Brain Metastases | EGFR Activating MutationChina